MicroSectors Gold Miners -3X Inverse Leveraged ETNs

ARK Innovation ETF

Direxion Daily S&P Biotech Bull 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Gold Miners Bear 3X ETF

Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

Direxion Daily 20+ Yr Trsy Bear 3X ETF

VS TR -1x Short VIX Futures ETF

MicroSectors Gold Miners 3X Leveraged ETN

VS TR 2x Long VIX Futures ETF

Direxion Daily S&P Biotech Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily Gold Miners Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily Small Cap Bear 3X ETF

Direxion Financial Bear 3X Shar

Archer Aviation Inc. Class A Common Stock

AgEagle Aerial Systems Inc. Common Stock

ChargePoint Holdings Inc. Common Stock

Dana Incorporated Common Stock

Reddit Inc. Class A Common Stock

Hims & Hers Health Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Oklo Inc.

Northern Oil and Gas Inc. Common Stock

Noble Corporation plc A Ordinary Shares

Endeavour Silver Corporation Ordinary Shares (Canada)

Agnico Eagle Mines Limited Common Stock

Gold Fields Limited American Depositary Shares

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Hilton Grand Vacations Inc. Common Stock

New Gold Inc.

Eldorado Gold Corporation Ordinary Shares

Hecla Mining Company Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Century Communities Inc. Common Stock

Click here to get full coverage on Insider Purchase: Director at $IMUX Buys 70,000 Shares - Nasdaq

Insider Purchase: Director at $IMUX Buys 70,000 Shares  Nasdaq

Insider Purchase: Director at $IMUX Buys 70,000 Shares - Nasdaq

Click here to get full coverage on Immunic's MS Drug Shows 34% Disease Progression Reduction as Phase 3 Enrollment Hits Major Milestone - Stock Titan

Immunic's MS Drug Shows 34% Disease Progression Reduction as Phase 3 Enrollment Hits Major Milestone  Stock Titan

Immunic's MS Drug Shows 34% Disease Progression Reduction as Phase 3 Enrollment Hits Major Milestone - Stock Titan

Click here to get full coverage on Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI - Proactive financial news

Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI  Proactive financial news

Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI - Proactive financial news

Click here to get full coverage on Immunic to Participate in Investor, Scientific and Industry Conferences in June - Yahoo Finance

Immunic to Participate in Investor, Scientific and Industry Conferences in June  Yahoo Finance

Immunic to Participate in Investor, Scientific and Industry Conferences in June - Yahoo Finance

Click here to get full coverage on Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Capital | IMUX Stock News - GuruFocus

Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Capital | IMUX Stock News  GuruFocus

Immunic (IMUX) Receives Continued 'Buy' Rating from D. Boral Capital | IMUX Stock News - GuruFocus

Click here to get full coverage on Immunic to Participate in Investor, Scientific and Industry Conferences in June - Quantisnow

Immunic to Participate in Investor, Scientific and Industry Conferences in June  Quantisnow

Immunic to Participate in Investor, Scientific and Industry Conferences in June - Quantisnow

Click here to get full coverage on Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st

Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future  simplywall.st

Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st

Click here to get full coverage on Immunic Therapeutics reaches major milestone with completion of ENSURE Trial Enrollment - Proactive Investors

Immunic Therapeutics reaches major milestone with completion of ENSURE Trial Enrollment  Proactive Investors

Immunic Therapeutics reaches major milestone with completion of ENSURE Trial Enrollment - Proactive Investors

Click here to get full coverage on Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering  Eastern Progress

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress

Click here to get full coverage on Immunic Showcases Breakthrough MS Drug Data at 6 Major Healthcare Conferences This Month - Stock Titan

Immunic Showcases Breakthrough MS Drug Data at 6 Major Healthcare Conferences This Month  Stock Titan

Immunic Showcases Breakthrough MS Drug Data at 6 Major Healthcare Conferences This Month - Stock Titan

Click here to get full coverage on IMUX Completes Enrollment for Phase 3 Trials in Multiple Scleros - GuruFocus

IMUX Completes Enrollment for Phase 3 Trials in Multiple Scleros  GuruFocus

IMUX Completes Enrollment for Phase 3 Trials in Multiple Scleros - GuruFocus

Click here to get full coverage on Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering | IMUX Stock News - GuruFocus

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering | IMUX Stock News  GuruFocus

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering | IMUX Stock News - GuruFocus

Click here to get full coverage on Biotech Immunic Launches Strategic Public Offering to Advance Inflammatory Disease Pipeline - Stock Titan

Biotech Immunic Launches Strategic Public Offering to Advance Inflammatory Disease Pipeline  Stock Titan

Biotech Immunic Launches Strategic Public Offering to Advance Inflammatory Disease Pipeline - Stock Titan

Click here to get full coverage on IMUX: Promising Results of Vidofludimus Calcium in Multiple Sclerosis Treatment | IMUX Stock News - GuruFocus

IMUX: Promising Results of Vidofludimus Calcium in Multiple Sclerosis Treatment | IMUX Stock News  GuruFocus

IMUX: Promising Results of Vidofludimus Calcium in Multiple Sclerosis Treatment | IMUX Stock News - GuruFocus

Click here to get full coverage on Immunic Secures Massive $195M Potential Funding: Oversubscribed Offering Signals Strong Investor Confidence - Stock Titan

Immunic Secures Massive $195M Potential Funding: Oversubscribed Offering Signals Strong Investor Confidence  Stock Titan

Immunic Secures Massive $195M Potential Funding: Oversubscribed Offering Signals Strong Investor Confidence - Stock Titan

Click here to get full coverage on Immunic releases June conference schedule - Proactive Investors

Immunic releases June conference schedule  Proactive Investors

Immunic releases June conference schedule - Proactive Investors

Click here to get full coverage on Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | IMUX S - GuruFocus

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | IMUX S  GuruFocus

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS | IMUX S - GuruFocus

Click here to get full coverage on Immunic Lands $5.1M Institutional Backing: Aberdeen Investments Takes Major Stake - Stock Titan

Immunic Lands $5.1M Institutional Backing: Aberdeen Investments Takes Major Stake  Stock Titan

Immunic Lands $5.1M Institutional Backing: Aberdeen Investments Takes Major Stake - Stock Titan

Click here to get full coverage on Immunic raises $65M in public offering to fund clinical trials - Proactive Investors

Immunic raises $65M in public offering to fund clinical trials  Proactive Investors

Immunic raises $65M in public offering to fund clinical trials - Proactive Investors

Click here to get full coverage on Immunic's Game-Changing MS Treatment Takes Center Stage at Two Global Conferences - Stock Titan

Immunic's Game-Changing MS Treatment Takes Center Stage at Two Global Conferences  Stock Titan

Immunic's Game-Changing MS Treatment Takes Center Stage at Two Global Conferences - Stock Titan

Click here to get full coverage on William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation - Nasdaq

William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation  Nasdaq

William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation - Nasdaq

Click here to get full coverage on Immunic Reveals New Clinical Data for Celiac Disease and MS Drugs at Three Major Medical Conferences - Stock Titan

Immunic Reveals New Clinical Data for Celiac Disease and MS Drugs at Three Major Medical Conferences  Stock Titan

Immunic Reveals New Clinical Data for Celiac Disease and MS Drugs at Three Major Medical Conferences - Stock Titan

Click here to get full coverage on Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials - Proactive Investors

Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials  Proactive Investors

Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials - Proactive Investors

Click here to get full coverage on Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX) - Seeking Alpha

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX)  Seeking Alpha

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX) - Seeking Alpha

Click here to get full coverage on Immunic (IMUX) Price Target Raised to $22 by Brookline Following Positive Trial Data | IMUX Stock News - GuruFocus

Immunic (IMUX) Price Target Raised to $22 by Brookline Following Positive Trial Data | IMUX Stock News  GuruFocus

Immunic (IMUX) Price Target Raised to $22 by Brookline Following Positive Trial Data | IMUX Stock News - GuruFocus

Click here to get full coverage on Director Makes Bold Move with Massive Immunic Stock Purchase - TipRanks

Director Makes Bold Move with Massive Immunic Stock Purchase  TipRanks

Director Makes Bold Move with Massive Immunic Stock Purchase - TipRanks

Click here to get full coverage on Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering - GuruFocus

Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering  GuruFocus

Immunic (IMUX) Faces Price Target Reduction Amid Stock Offering - GuruFocus

Click here to get full coverage on Immunic (IMUX) Receives Target Price Adjustment from D. Boral Capital | IMUX Stock News - GuruFocus

Immunic (IMUX) Receives Target Price Adjustment from D. Boral Capital | IMUX Stock News  GuruFocus

Immunic (IMUX) Receives Target Price Adjustment from D. Boral Capital | IMUX Stock News - GuruFocus

Click here to get full coverage on Immunic (IMUX) Launches Public Offering with Warrant Options | I - GuruFocus

Immunic (IMUX) Launches Public Offering with Warrant Options | I  GuruFocus

Immunic (IMUX) Launches Public Offering with Warrant Options | I - GuruFocus

Click here to get full coverage on Immunic (IMUX) Launches Public Offering with Pre-Funded and Warrants | IMUX Stock News - GuruFocus

Immunic (IMUX) Launches Public Offering with Pre-Funded and Warrants | IMUX Stock News  GuruFocus

Immunic (IMUX) Launches Public Offering with Pre-Funded and Warrants | IMUX Stock News - GuruFocus

Click here to get full coverage on Immunic to Participate in Investor, Scientific and Industry Conf - GuruFocus

Immunic to Participate in Investor, Scientific and Industry Conf  GuruFocus

Immunic to Participate in Investor, Scientific and Industry Conf - GuruFocus

Click here to get full coverage on Immunic Approves Equity Plan Amendment at Annual Meeting - TipRanks

Immunic Approves Equity Plan Amendment at Annual Meeting  TipRanks

Immunic Approves Equity Plan Amendment at Annual Meeting - TipRanks

Click here to get full coverage on Breakthrough in Primary Progressive MS: Clinical Trial Shows 30% Reduced Disability Risk - Stock Titan

Breakthrough in Primary Progressive MS: Clinical Trial Shows 30% Reduced Disability Risk  Stock Titan

Breakthrough in Primary Progressive MS: Clinical Trial Shows 30% Reduced Disability Risk - Stock Titan

Click here to get full coverage on We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully - Yahoo Finance

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully  Yahoo Finance

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully - Yahoo Finance

Click here to get full coverage on Immunic (IMUX) Launches $65M Public Offering, Shares Drop - GuruFocus

Immunic (IMUX) Launches $65M Public Offering, Shares Drop  GuruFocus

Immunic (IMUX) Launches $65M Public Offering, Shares Drop - GuruFocus

Click here to get full coverage on Top Executives Make Bold Moves with Major Immunic Stock Purchases! - TipRanks

Top Executives Make Bold Moves with Major Immunic Stock Purchases!  TipRanks

Top Executives Make Bold Moves with Major Immunic Stock Purchases! - TipRanks

Click here to get full coverage on Immunic (IMUX) Price Target Lowered by B. Riley Securities | IMU - GuruFocus

Immunic (IMUX) Price Target Lowered by B. Riley Securities | IMU  GuruFocus

Immunic (IMUX) Price Target Lowered by B. Riley Securities | IMU - GuruFocus

Click here to get full coverage on IMUX - Immunic Inc Latest Stock News & Market Updates - Stock Titan

IMUX - Immunic Inc Latest Stock News & Market Updates  Stock Titan

IMUX - Immunic Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Immunic Secures $240M Funding as Multiple Sclerosis Drug Trials Show Promise in Phase 3 - Stock Titan

Immunic Secures $240M Funding as Multiple Sclerosis Drug Trials Show Promise in Phase 3  Stock Titan

Immunic Secures $240M Funding as Multiple Sclerosis Drug Trials Show Promise in Phase 3 - Stock Titan

Click here to get full coverage on Immunic (IMUX) Shares Fall on Phase 2 Trial Results for Multiple Sclerosis Drug - GuruFocus

Immunic (IMUX) Shares Fall on Phase 2 Trial Results for Multiple Sclerosis Drug  GuruFocus

Immunic (IMUX) Shares Fall on Phase 2 Trial Results for Multiple Sclerosis Drug - GuruFocus

Click here to get full coverage on HC Wainwright & Co. Initiates Coverage of Immunic (IMUX) with Buy Recommendation - Nasdaq

HC Wainwright & Co. Initiates Coverage of Immunic (IMUX) with Buy Recommendation  Nasdaq

HC Wainwright & Co. Initiates Coverage of Immunic (IMUX) with Buy Recommendation - Nasdaq

Click here to get full coverage on Immunic, Inc. Announces Proposed Public Offering - Quantisnow

Immunic, Inc. Announces Proposed Public Offering  Quantisnow

Immunic, Inc. Announces Proposed Public Offering - Quantisnow

Click here to get full coverage on Immunic unveils pricing of $65M underwritten public offering - Proactive financial news

Immunic unveils pricing of $65M underwritten public offering  Proactive financial news

Immunic unveils pricing of $65M underwritten public offering - Proactive financial news

Click here to get full coverage on We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - simplywall.st

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate  simplywall.st

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - simplywall.st

Click here to get full coverage on Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Quantisnow

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering  Quantisnow

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Quantisnow

Click here to get full coverage on Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering  Eastern Progress

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Eastern Progress

Click here to get full coverage on Immunic drops after mid-stage trial data for multiple sclerosis drug - Seeking Alpha

Immunic drops after mid-stage trial data for multiple sclerosis drug  Seeking Alpha

Immunic drops after mid-stage trial data for multiple sclerosis drug - Seeking Alpha

Click here to get full coverage on Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - Yahoo Finance

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial  Yahoo Finance

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - Yahoo Finance

Click here to get full coverage on Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - Yahoo Finance

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments  Yahoo Finance

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - Yahoo Finance

Click here to get full coverage on Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un - GuruFocus

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un  GuruFocus

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Un - GuruFocus

Click here to get full coverage on Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq

Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts  Nasdaq

Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq

Click here to get full coverage on Immunic to raise up to $65M in underwritten public offering - Proactive Investors

Immunic to raise up to $65M in underwritten public offering  Proactive Investors

Immunic to raise up to $65M in underwritten public offering - Proactive Investors

Click here to get full coverage on Immunic Announces Public Offering to Fund Trials - TipRanks

Immunic Announces Public Offering to Fund Trials  TipRanks

Immunic Announces Public Offering to Fund Trials - TipRanks

Click here to get full coverage on Immunic eyes Phase 3 after MS disability gains in Phase 2 CALLIPER trial - Proactive financial news

Immunic eyes Phase 3 after MS disability gains in Phase 2 CALLIPER trial  Proactive financial news

Immunic Inc (IMUX)

Price Chart

Key Statistics

Technicals

About IMUX

Latest News

Insider Purchase: Director at $IMUX Buys 70,000 Shares - Nasdaq

Immunic's MS Drug Shows 34% Disease Progression Reduction as Phase 3 Enrollment Hits Major Milestone - Stock Titan

Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI - Proactive financial news

Advanced Charts

Top Gainers

Top Losers